Management Credibility Analysis

Unavailable
Verified Management Score Unavailable
Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed
Verified Catalysts Unavailable
No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive
Not disclosed
Headquarters
7 BD HAUSSMANN, PARIS
Founded
Not disclosed

📈 Company Timeline

Major business events
Positive
Negative
Neutral
14 Aug 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in ABIVAX Société Anonyme.

13 Aug 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in ABIVAX Société Anonyme.

7 Jul 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in ABIVAX Société Anonyme.

11 May 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in ABIVAX Société Anonyme.

23 Mar 2026

ABIVAX Société Anonyme securities registration filing

ABIVAX Société Anonyme filed a registration or prospectus document concerning securities.

Capital Structure & Financial Position

Financial strength and liquidity analysis
Verified Capital Structure Unavailable
Balance-sheet, credit-rating, debt, and capital-activity data require sourced financial statement ingestion.

Peer Comparison - Health Care

Company Price Market Cap
LLY - Eli Lilly and Company $1,276.13
Yahoo Finance 		$1.20T
JNJ - Johnson & Johnson $256.74
Yahoo Finance 		$618.71B
ABBV - AbbVie Inc. $284.80
Yahoo Finance 		$503.28B
UNH - UnitedHealth Group Incorporated $418.43
Yahoo Finance 		$375.58B
MRK - Merck & Co., Inc. $148.55
Yahoo Finance 		$366.50B

📋 Corporate Actions

Recent and upcoming corporate events
Verified Corporate Actions Unavailable
Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis
Verified Financial Statements Unavailable
Verified financial statement data is not ingested for this stock yet.

Analyst Consensus

Buy
Target: $156.43
78.8% upside potential
📈
Strong Buy
Unavailable
👍
Buy
6
⏸️
Hold
1
📉
Sell
0
7 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved Targets range 118.00–180.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments
Verified Dividend Data Unavailable
Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable
Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity
Verified Insider Transactions Unavailable
Director and insider transaction data is not ingested for this stock yet.

Top Shareholders

Tcg Crossover Management, Llc
6,007,834 shares
-7.302% change
6/30/2026
Darwin Global Management, Ltd.
3,621,583 shares
4.409% change
6/30/2026
Helikon Investments Ltd
2,787,131 shares
175.048% change
6/30/2026
Vestal Point Capital, Lp
2,349,443 shares
56.63% change
6/30/2026
Jupiter Topco Llc
1,913,933 shares
New% change
6/30/2026
Ubs Group Ag
1,844,918 shares
-59.429% change
6/30/2026
Adar1 Capital Management, Llc
1,804,703 shares
29.46% change
6/30/2026
Caligan Partners Lp
1,557,924 shares
6.567% change
6/30/2026
Citadel Advisors Llc
1,438,352 shares
164.239% change
6/30/2026
Morgan Stanley
1,432,185 shares
-15.999% change
6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed · 2 days ago